Seminars in Hematology
Volume 37, Issue 1 , Pages 15-29 , January 2000

Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?

  • John Barrett

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John Barrett, MD, Bldg 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.
    • From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Bone Marrow Transplant Unit, M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Yogen Saunthararajah

      Affiliations

    • From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Bone Marrow Transplant Unit, M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Jeffrey Molldrem

      Affiliations

    • From the Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • From the Bone Marrow Transplant Unit, M.D. Anderson Cancer Center, Houston, TX, USA

References 

  1. Anan K, Ito M, Misawa M, et al.  Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene. Br J Haematol. 1995;89:838–844
  2. Appelbaum FR, Barrall J, Storb R, et al.  Clonal cytogenetic abnormality in a patient with otherwise typical aplastic anemia. Exp Hematol. 1989;15:1134–1139
  3. Asano H, Ohashi H, Ichihara M, et al.  Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood. 1994;84:588–594
  4. Asano H, Ohashi H, Kinoshita K, et al.  Nonclonal hematopoietic progenitor cells in bone marrow of patients with myelodysplastic syndrome. In:  Nomura T,  Yoshida Y editor. Myelodysplastic Syndromes: Advances in Research and Treatment. Amsterdam, The Netherlands: Elsevier Science; 1995;p. 129–134
  5. Ascensão J, Pahwa R, Kagan W, et al.  Inhibition of bone marrow colony growth by antilymphocyte globulin. Lancet. 1976;1:669–672
  6. Bennett JM, Catovsky DG, Flandrin DAG, et al.  Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  7. Biesma DH, Van den Tweel JG, Verdonck LF, et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548–1551
  8. Bose S, Deininger M, Gora-Tybor J, Goldman JM, et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362–3367
  9. Bouscary D, De Vos J, Guesnu M, et al.  Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839–845
  10. Brodsky RA, Sensenbrenner LL, Jones RL. Complete remission in severe aplastic anemia after cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491–494
  11. Carella A, Dejana A, Lerma E, et al.  In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol. 1996;95:127–130
  12. Carlo-Stella C, Cazzola M, Bergamaschi G, et al.  Growth of human hematopoietic colonies from patients with myelodys-plastic syndromes in response to recombinant human granulocyte-macrophage colony stimulating factor. Leukemia. 1989;3:363–366
  13. Dan K, An E, Futaki M, et al.  Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Hematol. 1993;89:113–118
  14. De Planque MM, van Krieken JHJM, Kluin-Nelemans HC, et al.  Bone marrow histopathology of patients with severe aplastic anemia before treatment and at follow-up. Br J Haematol. 1989;72:439–444
  15. Dunn DE, Tanawattacharoen P, Boccuni P, et al.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401–408
  16. Elghetany MT, Hudnall SD, Gardner FH, et al.  Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: An additional tool for differential diagnosis. Haematologica. 1997;82:21–24
  17. Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, et al.  Hematopoietic progenitor cells from patients with myelodysplastic syndromes: In vitro colony growth and long-term proliferation. Leuk Res. 1999;23:385–394
  18. Fohlmeister I, Fischer R, Modder B, et al.  Aplastic anemia and the hypocellular myelodysplastic syndrome: Histomorphological, diagnostic and prognostic features. J Clin Pathol. 1985;38:1218–1224
  19. Frickhofen N, Kaltwasser JP, Schretzenmeier H, et al.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–1304
  20. Frisch B, Lewis SM. The bone marrow in aplastic anemia: Diagnostic and prognostic features. J Clin Pathol. 1974;27:231–241
  21. Fuchs D, Denz HA, Nachbauer D, et al.  Circulating gamma-interferon in patients with aplastic anemia. Blood. 1989;73:858–859
  22. Geissler K, Hinterberger W, Jager U, et al.  Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. Blut. 1988;57:45–49
  23. Gersuk GM, Beckham C, Ioken MR, et al.  A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176–188
  24. Gluckman E, Devergie A, Faille A, et al.  Treatment of severe aplastic anemia with antilymphocyte globulin and androgens. Exp Hematol. 1978;6:679–686
  25. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al.  Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540–2546
  26. Greenberg PL, Cox C, Le Beau M, et al.  International survival score for evaluating prognosis in MDS. Blood. 1997;89:2079–2088
  27. Harstock RJ, Smith EB, Petty CS. Normal variations with ageing of the amount of hematopoietic tissue in bone marrow from the ilica crest. Am J Clin Pathol. 1965;43:326–331
  28. Herrmann F, Griffin JD, Meuer SG, et al.  Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol. 1986;136:1629–1634
  29. Horikawa K, Nakakuma H, Kawaguchi T, et al.  Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood. 1997;90:2716–2722
  30. Hotta T. Clonality in hematopoietic disorders. Int J Hematol. 1997;66:403–412
  31. Hsu HC, Tsai WTH, Chen LY, et al.  Production of hematopoietic regulatory cytokines by peripheral blood mono-nuclear cells in patients with aplastic anemia. Exp Hematol. 1996;24:31–36
  32. Imai Y, Fukuoka T, Nakatani A, et al.  Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone. Br J Haematol. 1996;93:146–150
  33. Ito T, Ohashi H, Kagami Y, et al.  Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndrome following successful chemotherapy. Leukemia. 1994;8:839–843
  34. Iwanga M, Furukawa K, Amenomori T, et al.  Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102:465–474
  35. Jonas̃ova A, Neuwirtova R, Cermak J, et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304–309
  36. Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma. 1996;23:253–266
  37. Kearney L. The impact of the new FISH technologies on the cytogenetics of hematological malignancies. Br J Haematol. 1999;104:648–658
  38. Kearns WG, Liu J, Aridgides L, et al.  Genomic instability in bone marrow failure syndromes: High frequency of aneuploidy by fluorescence in situ hybridization and identification of a spindle checkpoint gene mutation. Blood. 1999;(suppl 1): abstr (in press)
  39. Kitagawa M, Saito I, Kuwata T, et al.  Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049–2054
  40. Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. In: ed 2. Semin Hematol. 33:1996;p. 95–110
  41. Kourilsky P, Claverie JM. MHC-antigen interaction: What does the T cell receptor see?. Adv Immunol. 1989;45:107–115
  42. Kuriyama K, Tomonaga M, Matsuo T, et al.  Diagnostic significance of detecting pseudo Pelger-Huet anomalies and micromegakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–671
  43. Leeksma OC, Thomas LL, van der Lelie J, et al.  Effectiveness of low dose cyclosporine in acquired aplastic anaemia with severe neutropenia. Neth J Med. 1992;41:143–148
  44. Lepelley P, Grardel N, Erny O, et al.  Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma. 1998;30:307–312
  45. Maciejewski JP, Anderson S, Katevas P, et al.  Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol. 1994;87:227–234
  46. Maciejewski JP, Selleri C, Cato T, et al.  A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983–1991
  47. Maciejewski JP, Selleri C, Sato T, et al.  Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245–252
  48. Maciejewski JP, Hibbs JR, Anderson S, et al.  Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102–1110
  49. Mangi MH, Mufti GJ. Primary myelodysplastic syndromes: Diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood. 1992;79:198–205
  50. Manz CY, Dietrich PY, Schnuriger V, et al.  T-cell receptor beta chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis. 1997;23:110–122
  51. Maschek H, Georgii A, Kaloutsi V, et al.  Myelofibrosis in primary myelodysplastic syndromes: A retrospective study of 352 patients. Eur J Haematol. 1992;48:208–214
  52. Maschek H, Kalousti V, Rodriguez-Kaiser M, et al.  Hypoplastic myelodysplastic syndrome: Incidence, morphology, cytogenetics, and prognosis. Ann Hematol. 1993;66:117–122
  53. Mathé G, Amiel JL, Schwartzenberg L, et al.  Bone marrow graft in man after conditioning by antilymphocyte serum. Br Med J. 1970;2:131–136
  54. Mecucci C, Rege-Cambrin G, Michaux JL, et al.  Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br J Haematol. 1986;64:699–706
  55. Mehta J, Singhal S, Mehta BC, et al.  Low-dose cyclosporin for severe aplastic anemia. Am J Hematol. 1992;40:73–77
  56. Melenhorst JJ, Fibbe WE, Struyk L, et al.  Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia. Br J Haematol. 1997;96:85–91
  57. Mikhailova N, Sessarego M, Fugazza G, et al.  Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81:418–422
  58. Moebius U, Herrmann F, Hercend T, et al.  Clonal analysis of T cells in a patient with aplastic anemia. J Clin Invest. 1991;87:1567–1574
  59. Molldrem JJ, Caples M, Mavroudis D, et al.  Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699–705
  60. Molldrem JJ, Jiang YZ, Stetler-Stevenson MA, et al.  Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V beta profiles. Br J Haematol. 1998;102:1314–1322
  61. Najean Y. Anemies aplastiques. In:  Breton-Gorius J,  Reyes F,  Rochant H, et al. editor. L'Hematologie de Bernard Dreyfus. Paris, France: Flammarion; 1992;p. 705–721
  62. Nakao S, Takamatsu H, Yachie A, et al.  Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia. Exp Hematol. 1995;23:433–438
  63. Nand S, Goodwin JE. Hypoplastic myelodysplastic syndrome. Cancer. 1988;62:958–964
  64. Narayanan MN, Geary CG, Freemont AJ, et al.  Long-term follow-up of aplastic anaemia. Br J Haematol. 1994;86:837–843
  65. Negendank W, Weissman D, Bey TM, et al.  Evidence for clonal disease by magnetic resonance imaging in patients with hypoplastic marrow disorders. Blood. 1991;78:2872–2879
  66. Nisticò A, Young NS. Gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120:463–469
  67. Ohno Y, Takahashi Y, Yoshida Y. Ferrokinetics and bone marrow scanning in patients with myelodysplastic syndrome, hypolastic myelodysplastic syndrome and aplastic anemia. (in Japanese) Rinsho Ketsueki. 1993;34:260–264
  68. Orazi A, Albitar M, Heerema NA, et al.  Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107:268–274
  69. Piedras J, Hernandez G, Lopez-Karpovitch X. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes. Am J Hematol. 1998;57:113–118
  70. Raghavachar A, Janssen JW, Schretzenmeier H, et al.  Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. Blood. 1995;86:2938–2947
  71. Rosenfeld SJ, Kimball J, Vining D, et al.  Intensive immuno-suppression with antithymocyte globulin and cyclosporine for severe acquired aplastic anemia. Blood. 1995;85:3058–3065
  72. Sato T, Kim S, Selleri C, et al.  Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia. 1998;12:1187–1194
  73. Saunthararajah Y, Caples M, Barrett AJ. ATG induced complete remission in a case of MDS/leukemia. Blood. 1998;92(suppl 1):245; abstr
  74. Schretzenmeier H, Jenal M, Herrmann F, et al.  Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood. 1996;88:4474–4480
  75. Schultz JC, Shahidi NT. Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia. Am J Hematol. 1994;45:32–38
  76. Smith MA, Smith JG. The occurrence subtype and significance of hemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res. 1991;5:597–601
  77. Socié G. Could aplastic anaemia be considered a pre-preleukaemic disorder?. Eur J Haematol. 1996;60:60–63 (suppl)
  78. Stoppa AM, Vey N, Sainty D, et al.  Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: Absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. Br J Haematol. 1996;93:42–44
  79. Stryckmans PA, Dumont JP, Velu T, et al.  Cyclosporine in refractory severe aplastic anemia. N Engl J Med. 1984;310:655–656
  80. Sugarawa T, Endo K, Shishido T, et al.  T-cell mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol. 1992;41:304–305
  81. Tamai Y, Takami H, Nakahata R, et al.  Hematological characteristics of hypoplastic MDS patients with chromosomal abnormalities, who had been followed for aplastic anemia with normal karyotypes. (in Japanese) Rinsho Ketsueki. 1997;38:1243–1248
  82. Tichelli A, Gratwohl A, Wuersch A, et al.  Antilymphocyte globulin for myelodysplastic syndrome?. Br J Haematol. 1988;68:139–140
  83. Tichelli A, Gratwohl A, Nissen C, et al.  Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin. Blood. 1992;80:337–345
  84. Tricot G, De Wolf-Peeters C, Vlietinck R, et al.  Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984;58:217–225
  85. Tsuge I, Kojima S, Matsuoka H, et al.  Clonal haematopoiesis in children with acquired aplastic anaemia. Br J Haematol. 1993;84:137–143
  86. Tuzuner N, Bennett JM. Reference standards for bone marrow cellularity. Leuk Res. 1994;18:645–646
  87. Tuzuner N, Cox C, Rowe JM, et al.  Hypocellular MDS: New proposals. Br J Haematol. 1995;91:612–617
  88. Van der Schoot CE, Hiuzinger TWJ, Van't Veer-Korthof ET, et al.  Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorimeytric assay. Blood. 1990;76:1853–1859
  89. van Kamp H, Landegent JE, Jansen RP, et al.  Clonal hematopoiesis in patients with acquired aplastic anemia. Blood. 1991;78:3209–3214
  90. van Kamp H, Landegent JE, Jansen RP, et al.  Myelodysplasia following paroxysmal nocturnal haemoglobinuria: Evidence for the emergence of a separate clone. Br J Haematol. 1994;87:399–400
  91. Ueda H, Tashiro S, Kojima S, et al.  Instability of chromosome 7 in colony forming cells of patients with aplastic anemia. Int J Hematol. 1999;70:13–19
  92. Watari K, Asano S, Shirafuji N, et al.  Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood. 1989;73:117–122
  93. Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood. 1992;79:1385–1392
  94. Young N, Griffith P, Brittain E, et al.  A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988;72:1861–1869
  95. Young NS, Barrett AJ. Perspective: The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367–3377
  96. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365–12372

☆ This is a US government work. There are no restrictions to its use.

PII: S0037-1963(00)90027-1

Seminars in Hematology
Volume 37, Issue 1 , Pages 15-29 , January 2000

Article Tools